Table 2.

Comparison of Negative Conversion Between Patients Treated With and Without Nirmatrelvir/Ritonavir

Patients	Total	No. (%) With a Negative Conversiona	Negative Conversion ≤15 Days After Symptom Onseta
			Model 1b	Model 2c
			HR (95% CI)	HR (95% CI)
Without treatment	224	94 (42.0)	Reference	Reference
Treated with nirmatrelvir/ritonavir ≤5 d	175	157 (89.7)	4.33 (3.31–5.65)	4.85 (3.56–6.61)
Treated with nirmatrelvir/ritonavir >5 d	83	43 (51.8)	1.29 (.90–1.86)	1.47 (1.02–2.13)

Abbreviations: CI, confidence interval; HR, hazard ratio.

All patients were followed from symptom onset to negative conversion or day 15, whichever was earliest.

Model 1: adjusted for patient’s age and sex.

Model 2: adjusted for all patients’ baseline characteristics (shown in Table 1).